03 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250603537539/en/Alto-Neuroscience-Announces-Acquisition-of-Novel-Dopamine-Agonist-Combination-Product-Candidate-Adding-Late-Stage-Readout-in-Treatment-Resistant-Depression-Within-Current-Cash-Runway
20 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/20/2901669/26135/en/Adial-Pharmaceuticals-Announces-Publication-in-Leading-Peer-Reviewed-Journal-Supporting-the-Potential-Efficacy-of-AD04-as-a-Precision-Medicine-for-the-Treatment-of-Alcohol-Use-Diso.html
06 Jun 2024
// HEALTH CANADA
https://recalls-rappels.canada.ca/en/alert-recall/accel-ondansetron-odt-4-8-mg-data-integrity-concerns-product-s-bioequivalence-data
13 Dec 2023
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf
01 May 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhills-rhb-102-bekinda-and-opaganib-granted-new-patents-in-oncology-setting-301811839.html
22 Feb 2023
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf